Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EUIncyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative Share XIncyte, MorphoSys’ CAR-T rival tafasitamab approved in EUhttps://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/
Novartis’ bid to extend Kymriah into earlier use hits a roadblockNovartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few Share XNovartis’ bid to extend Kymriah into earlier use hits a roadblockhttps://pharmaphorum.com/news/novartis-bid-to-extend-kymriah-into-earlier-use-hits-a-roadblock/
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLRoche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed Share XArmed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLhttps://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/
BMS will file for earlier-line use of Breyanzi in lymphoma after trial winBristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but Share XBMS will file for earlier-line use of Breyanzi in lymphoma after trial winhttps://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyIn 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the Share XAllogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyhttps://pharmaphorum.com/news/allogene-announces-pivotal-trial/
BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
FDA sets May date for verdict on ADC’s lymphoma drug LoncaADC Therapeutics could claim its first product approval in the US next May, after the FDA started a Share XFDA sets May date for verdict on ADC’s lymphoma drug Loncahttps://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/
Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
